2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

KEI Statement on Adoption of the WHA72 Transparency Resolution

Today the World Health Assembly (WHA) approved A72/A/CONF./2 Rev.1 as a resolution, titled “Improving the transparency of markets for medicines, vaccines, and other health products.” Link to the resolution: http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf When the text was made available, I sent out a… Continue Reading

WHA72: Portuguese Minister of Health, Marta Temido, underscores strong support for the WHO transparency resolution

On Monday, 20 May 2019, the Republic of Korea, Italy, Costa Rica, Greece, Indonesia, Italy, Mexico, Mongolia, Netherlands, Portugal, Republic of Korea, Saudi Arabia, Spain, and Vietnam convened an official side event at the 72nd session of the World Health… Continue Reading

24 May 2019 – KEI panel discussion – Assessing the implications of the development of new cell and gene-based therapies (including CAR T and CRISPR): What role should WHO play?

On Friday, 24 May 2019, Knowledge Ecology International (KEI) will convene an expert panel, “Assessing the implications of developments in cell and gene-based therapies (including CAR T and CRISPR): What role should WHO should play?” from 12h30 to 14h30 in… Continue Reading

Comparison between April 29, May 7, and May 10 versions of WHA 72 resolution on transparency

On Monday, May 13th, Politico published the latest version (May 10, 2019) of the transparency resolution noting the “dizzying number of brackets” in the latest text. The original sponsors are: Italy, Greece, Malaysia, Portugal, Serbia, Slovenia, South Africa, Spain, Turkey,… Continue Reading